Once again, AstraZeneca encounters CEO pay pushback
By Fraiser Kansteiner
AstraZeneca to invest 650 million pounds in UK to boost 'pandemic preparedness'
By Yadarisa Shabong and Muhammad Tasim Zahid
AstraZeneca to buy Amolyt Pharma for $1.05 bln to boost rare-disease portfolio
By Kirsten Donovan, Eva Mathews and Savio D'souza
US FDA approves Daiichi, AstraZeneca drug for treatment of solid tumors
By Christy Santhosh and Vijay Kishore
AstraZeneca to cap out-of-pocket inhaler costs in US, following rival Boehringer's move
By Puyaan Singh and Shilpi Majumdar
AstraZeneca signs deal for oral obesity drug and lifts profit outlook
By Donato Paolo Mancini
AstraZeneca pledges £650M in UK investments to boost vaccine capabilities, expand near HQ
By Angus Liu
AstraZeneca To Buy Amolyt Pharma for $1.05B To Expand Rare Disease Pipeline
By Fatima Attarwala
AstraZeneca bets on next-generation cancer therapy with $2 bln Fusion deal
By Manas Mishra and Yadarisa Shabong
AstraZeneca sued over jab: could it be down to a misunderstanding of how risk is calculated?
By Christian A. Yates
Judge rejects AstraZeneca’s challenge to Medicare drug price negotiations
By Annika Kim Constantino
AstraZeneca CEO Pascal Soriot's Pay Raises Questions for London
By Matthew Brooker
AstraZeneca: A case of steady-as-she-goes, says broker
By Ian Lyall and Philip Whiterow
Full Year and Q4 2023 results
By Pascal Soriot
AstraZeneca strikes $1bn deal to acquire its first vaccine company
By Hannah Kuchler and Donato Paolo Mancini
Astrazeneca says Catalent deal shows need for in-house capacity
By Maggie Fick and Eva Mathews
AstraZeneca buys Chinese CAR-T biotech Gracell in a $1.2bn deal
By Phalguni Deswal
AstraZeneca to buy China's Gracell Biotechnologies in $1.2 billion deal
By Urvi Dugar and Christy Santhosh
AstraZeneca raises stakes in obesity drug race with Eccogene deal
By Ludwig Burger and Maggie Fick
AstraZeneca ups profit outlook and boosts anti-obesity pipeline
By Maggie Fick and Eva Mathews
U.S. FDA approves AstraZeneca's Tagrisso-chemo combo
By Gursimran Kaur
AstraZeneca targets 2024 growth but mixed views hit shares
By Maggie Fick and Eva Mathews
AstraZeneca, Atlassian and Philips: How to convince suppliers to lower greenhouse gas emissions
By Heather Clancy
Why some people got blood clots after the AstraZeneca vaccine – new clues
By Richard Buka and Samantha J Montague
AstraZeneca sues Arkansas to block drug-discount program
By Mike Scarcella
FTSE 100 retreats as AstraZeneca earnings disappoint
By Sruthi Shankar and Khushi Singh
AstraZeneca says no supply snags so far from Red Sea disruptions
By Divya Chowdhury and Savio Shetty
AstraZeneca to invest $300 million in US facility for cell therapies
By Sriparna Roy and Shounak Dasgupta